XBiotech, Inc. (XBIT)
1.91
-0.06
(-3.05%)
USD |
NASDAQ |
Oct 23, 16:00
1.91
0.00 (0.00%)
After-Hours: 20:00
XBiotech Enterprise Value : -49.47M for Oct. 22, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 22, 2026 | -49.47M |
| October 21, 2026 | -48.86M |
| October 20, 2026 | -47.94M |
| October 19, 2026 | -48.55M |
| October 16, 2026 | -44.89M |
| October 15, 2026 | -43.67M |
| October 14, 2026 | -43.67M |
| October 13, 2026 | -43.67M |
| October 12, 2026 | -39.71M |
| October 09, 2026 | -39.71M |
| October 08, 2026 | -42.46M |
| October 07, 2026 | -42.76M |
| October 06, 2026 | -43.67M |
| October 05, 2026 | -43.06M |
| October 02, 2026 | -42.76M |
| October 01, 2026 | -42.46M |
| September 30, 2026 | -42.76M |
| September 29, 2026 | -43.06M |
| September 28, 2026 | -43.98M |
| September 25, 2026 | -43.37M |
| September 24, 2026 | -43.67M |
| September 23, 2026 | -43.06M |
| September 22, 2026 | -43.06M |
| September 21, 2026 | -43.06M |
| September 18, 2026 | -42.76M |
| Date | Value |
|---|---|
| September 17, 2026 | -43.06M |
| September 16, 2026 | -43.98M |
| September 15, 2026 | -42.61M |
| September 14, 2026 | -43.37M |
| September 11, 2026 | -42.76M |
| September 10, 2026 | -43.37M |
| September 09, 2026 | -43.06M |
| September 08, 2026 | -43.06M |
| September 04, 2026 | -42.46M |
| September 03, 2026 | -42.46M |
| September 02, 2026 | -42.76M |
| September 01, 2026 | -41.85M |
| August 31, 2026 | -39.41M |
| August 28, 2026 | -40.32M |
| August 27, 2026 | -39.41M |
| August 26, 2026 | -39.10M |
| August 25, 2026 | -39.41M |
| August 24, 2026 | -39.10M |
| August 21, 2026 | -40.02M |
| August 20, 2026 | -39.10M |
| August 19, 2026 | -39.10M |
| August 18, 2026 | -40.32M |
| August 17, 2026 | -39.10M |
| August 14, 2026 | -39.41M |
| August 13, 2026 | -38.49M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.613B |
| Alnylam Pharmaceuticals, Inc. | 30.07B |
| Anika Therapeutics, Inc. | 269.09M |
| Savara, Inc. | 789.89M |
| Vericel Corp. | 2.131B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.728M |
| Total Expenses (Quarterly) | 6.728M |
| EPS Diluted (Quarterly) | -0.2207 |
| Earnings Yield | -77.51% |
| Normalized Earnings Yield | -77.51 |